JP2019519599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519599A5 JP2019519599A5 JP2019510577A JP2019510577A JP2019519599A5 JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5 JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019510577 A JP2019510577 A JP 2019510577A JP 2019519599 A5 JP2019519599 A5 JP 2019519599A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- halo
- independently
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332280P | 2016-05-05 | 2016-05-05 | |
| US62/332,280 | 2016-05-05 | ||
| PCT/US2017/031367 WO2017193041A1 (en) | 2016-05-05 | 2017-05-05 | Modulators of the integrated stress pathway |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519599A JP2019519599A (ja) | 2019-07-11 |
| JP2019519599A5 true JP2019519599A5 (enExample) | 2020-06-25 |
| JP7003114B2 JP7003114B2 (ja) | 2022-01-20 |
Family
ID=58710118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510577A Expired - Fee Related JP7003114B2 (ja) | 2016-05-05 | 2017-05-05 | 統合ストレス経路のモジュレーター |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10836725B2 (enExample) |
| EP (1) | EP3452453B1 (enExample) |
| JP (1) | JP7003114B2 (enExample) |
| CN (1) | CN109689628A (enExample) |
| AR (1) | AR108393A1 (enExample) |
| AU (1) | AU2017260374B2 (enExample) |
| CA (1) | CA3023164A1 (enExample) |
| ES (1) | ES2923875T3 (enExample) |
| MA (1) | MA44866A (enExample) |
| TW (1) | TW201808903A (enExample) |
| UY (1) | UY37229A (enExample) |
| WO (1) | WO2017193041A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301709B2 (en) | 2017-08-09 | 2025-07-01 | Denali Therapeutics Inc | Compounds, compositions and methods |
| TW201920129A (zh) | 2017-09-01 | 2019-06-01 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| JP2021501785A (ja) | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| MX2020004538A (es) * | 2017-11-02 | 2020-09-18 | Calico Life Sciences Llc | Moduladores de la vía de estrés integrada. |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| US11166942B2 (en) | 2018-06-05 | 2021-11-09 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP2021529814A (ja) * | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| TW202545902A (zh) * | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| SG11202107871UA (en) * | 2019-02-25 | 2021-08-30 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| MX2021012904A (es) | 2019-04-23 | 2022-01-18 | Evotec Int Gmbh | Moduladores de la via de respuesta al estres integrada. |
| WO2020216766A1 (en) | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| CA3162526A1 (en) | 2020-01-28 | 2021-08-05 | Christopher John Brown | Modulators of the integrated stress response pathway |
| KR20220151635A (ko) | 2020-03-11 | 2022-11-15 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| EP4178955A1 (en) | 2020-07-11 | 2023-05-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| MX2023004677A (es) | 2020-10-22 | 2023-05-24 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| ES2997335T3 (en) | 2020-10-22 | 2025-02-17 | Evotec Int Gmbh | Modulators of the integrated stress response pathway |
| CA3195290A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| TW202241857A (zh) | 2020-12-18 | 2022-11-01 | 美商戴納立製藥公司 | 化合物之固體形式 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| US20070185079A1 (en) | 2004-01-07 | 2007-08-09 | Astrazeneca Ab | Therapeutic agents I |
| AU2005212073B2 (en) * | 2004-02-18 | 2010-07-08 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic amide derivatives |
| CA2594116A1 (en) * | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| WO2014144952A2 (en) | 2013-03-15 | 2014-09-18 | Peter Walter | Modulators of the eif2alpha pathway |
| WO2015038778A1 (en) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
-
2017
- 2017-05-04 TW TW106114863A patent/TW201808903A/zh unknown
- 2017-05-05 US US16/098,946 patent/US10836725B2/en active Active
- 2017-05-05 AU AU2017260374A patent/AU2017260374B2/en not_active Expired - Fee Related
- 2017-05-05 JP JP2019510577A patent/JP7003114B2/ja not_active Expired - Fee Related
- 2017-05-05 CN CN201780042045.7A patent/CN109689628A/zh active Pending
- 2017-05-05 CA CA3023164A patent/CA3023164A1/en not_active Abandoned
- 2017-05-05 EP EP17724209.6A patent/EP3452453B1/en active Active
- 2017-05-05 MA MA044866A patent/MA44866A/fr unknown
- 2017-05-05 WO PCT/US2017/031367 patent/WO2017193041A1/en not_active Ceased
- 2017-05-05 AR ARP170101181A patent/AR108393A1/es unknown
- 2017-05-05 ES ES17724209T patent/ES2923875T3/es active Active
- 2017-05-05 UY UY0001037229A patent/UY37229A/es not_active Application Discontinuation
-
2020
- 2020-09-30 US US17/038,179 patent/US20210269399A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515042A5 (enExample) | ||
| JP2019515043A5 (enExample) | ||
| JP2019530649A5 (enExample) | ||
| RU2018142740A (ru) | Модуляторы интегрированного сигнального пути стресса | |
| JP2013525433A5 (enExample) | ||
| JP2018515531A5 (enExample) | ||
| JP2019508407A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2013533884A5 (enExample) | ||
| AU2019217320B2 (en) | Steroid derivative regulators, method for preparing the same, and uses thereof | |
| AU2020355358A1 (en) | PROTAC small molecule compound and application thereof | |
| JP2021501789A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| WO2015101928A1 (en) | Fused thiophene and thiazole derivatives as ror gamma modulators | |
| CN114729044B (zh) | 毒蕈碱型乙酰胆碱m1受体拮抗剂 | |
| CA2797663A1 (en) | Compounds that modulate intracellular calcium | |
| JP2021501790A5 (enExample) | ||
| JP2020525512A (ja) | 癌および他の疾患を処置するためのＡＴＦ４阻害剤としての２−（４−クロロフェノキシ）−Ｎ−（（１−（２−（４−クロロフェノキシ）エチンアゼチジン（ｅｔｈｙｎａｚｅｔｉｄｉｎ）−３−イル）メチル）アセトアミド誘導体および関連化合物 | |
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| JP2021501781A5 (enExample) | ||
| EP3829561A1 (en) | Substituted-3h-imidazo[4,5-c]pyridine and 1h pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (enpp1) and stimulator for interferon genes (sting) modulators as cancer immunotherapeutics | |
| JP2013530236A5 (enExample) | ||
| HK1253029A1 (zh) | 作为毒蕈碱性受体4(m4)拮抗剂用於治疗神经系统疾病的n-[2-(1-苄基哌啶-4-基)乙基]-4-(吡嗪-2-基)-哌嗪-1-甲酰胺衍生物及相关化合物 | |
| MX2011006343A (es) | Tiazoles como ligandos del receptor de cannabinoide. | |
| MX2009009423A (es) | Derivados de 3-ciano-4-(4-fenil-piperidin-1-il)-piridin-2-ona. |